Comparison of irisin hormone expression between thyroid cancer tissues and oncocytic variant cells
Received 17 January 2019
Accepted for publication 25 February 2019
Published 28 March 2019 Volume 2019:11 Pages 2595—2603
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Cristina Weinberg
Peer reviewer comments 3
Editor who approved publication: Dr Ahmet Emre Eskazan
Kader Ugur,1 Suleyman Aydin,2 Tuncay Kuloglu,3 Gokhan Artas,4 Mehmet Ali Kocdor,5 İbrahim Sahin,2,6 Meltem Yardim,2 İbrahim Hanefi Ozercan4
1Department of Endocrinology and Metabolism Disease, School of Medicine, Firat University, Elazig, Turkey; 2Department of Medical Biochemistry and Clinical Biochemistry (Firat Hormones Research group), Firat University Hospital, Elazig, Turkey; 3Department of Histology and Embryology, School of Medicine, Firat University, Elazig, Turkey; 4Department of Pathology, School of Medicine, Firat University, Elazig, Turkey; 5Department of General Surgery, School of Medicine, Dokuz Eylul University, İzmir, Turkey; 6Department of Medical Biology, School of Medicine, Erzincan Binali Yildirim University, Erzincan, Turkey
Objective: The incidence of thyroid cancer has been continuously increasing. The main objective of this study was to investigate irisin expression in various thyroid pathologies and to compare these expression patterns with irisin expression in healthy thyroid tissues.
Methods: The study groups consisted of 20 cases each of control thyroid tissue, Hashimoto’s thyroiditis, thyroid papillary carcinoma, oncocytic papillary carcinoma, follicular thyroid carcinoma, oncocytic follicular thyroid carcinoma, medullary thyroid carcinoma, anaplastic thyroid carcinoma. Irisin expression was evaluated using immunohistochemistry. Irisin levels in thyroid tissue supernatants were measured using ELISA.
Results: Patients with HT showed increased irisin expression compared with controls (p<0.05). In addition, mild immunoreactivity was observed in the thyroid tissues of patients with papillary carcinoma while significantly increased irisin immunoreactivity was observed tissues of patients with oncocytic papillary carcinoma (p<0.05). There was no difference in irisin immunoreactivity in thyroid tissues between patients with follicular carcinoma and controls. However, irisin immunoreactivity was higher in tissues of patients with oncocytic follicular carcinoma than in tissues of patients with follicular carcinoma (p<0.05). No irisin immunoreactivity was observed in tissues of patients with medullary carcinoma, a malignant tumor the thyroid; however, irisin expression was significantly increased in tissues of patients with anaplastic carcinoma compared with that in tissues of controls (p<0.05). Furthermore, in all thyroid tissues with irisin expression, irisin immunoreactivity was observed in follicular cells, indicating that irisin is produced by these cells.
Conclusion: Irisin is a novel potential immunohistochemical marker for differentiating oncocytic variants of papillary and FTCs from papillary and follicular thyroid cancers.
Keywords: thyroid cancer, irisin, immunohistochemistry, diagnostic biomarker
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]